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Abstract: The reproducibility of contrast-enhanced ultrasound (CEUS) and standard B-mode 
ultrasound in the assessment of radiofrequency-ablated volume of benign thyroid nodules was 
compared. A preliminary study was conducted on consecutive patients who underwent 
radiofrequency ablation (RFA) of benign thyroid nodules between 2014 and 2016, with available 
CEUS and B-mode post-ablation checks. CEUS and B-mode images were retrospectively evaluated 
by two radiologists to assess inter- and intra-observer agreement in the assessment of ablated 
volume (Bland–Altman test). For CEUS, the mean inter-observer difference (95% limits of 
agreement) was 0.219 mL (-0.372–0.809 mL); for B-mode, the mean difference was 0.880 mL (-1.655–3.414 
mL). Reproducibility was significantly higher for CEUS (85%) than for B-mode (27%). Mean intra-
observer differences (95% limits of agreement) were 0.013 mL (0.803–4.097 mL) for Reader 1 and 
0.031 mL (0.763–3.931 mL) for Reader 2 using CEUS, while they were 0.567 mL (-2.180–4.317 mL, 
Reader 1) and 0.759 mL (-2.584–4.290 mL, Reader 2) for B-mode. Intra-observer reproducibility was 
significantly higher for CEUS (96% and 95%, for the two readers) than for B-mode (21% and 23%). 
In conclusion, CEUS had higher reproducibility and inter- and intra-observer agreement compared 
to conventional B-mode in the assessment of radiofrequency-ablated volume of benign thyroid 
nodules. 
Keywords: thyroid nodule; radiofrequency ablation; ultrasonography; contrast-enhanced 
ultrasound; observer variation 
 
J. Clin. Med. 2020, 9, 1504 2 of 9 
 
1. Introduction 
Thyroid nodules are a common occurrence in the general population, with a prevalence between 
20% and 70% [1–5]. The vast majority are benign and incidentally detected at ultrasound (US) 
examination. Although they are normally asymptomatic and can be managed conservatively (i.e., 
clinical and US follow-up), some of them may require treatment because of cosmetic reasons, 
subjective compressive symptoms (for compression on structures around the thyroid gland), or for 
an abnormally increased function of the nodule [1,6]. 
Surgery has been traditionally the main treatment option for thyroid nodules, carrying however 
several drawbacks, such as scars, need for general anesthesia, and risk of induced hypothyroidism 
[7]. Therefore, minimally invasive image-guided thermal ablation techniques have been increasingly 
applied in the last years in order to reduce the invasiveness of treatment in patients with benign 
thyroid nodules. Among image-guided thermal ablation techniques, laser and radiofrequency 
ablation (RFA) are the most commonly used [8,9]. Some guidelines and consensus documents 
suggested the application of image-guided thermal ablation as an alternative to surgery in patients 
with symptomatic thyroid nodules, even as first-line treatment [7,10,11]. 
Although thermal ablation is a safe and effective procedure, nodule regrowth can occur during 
follow-up, with a rate of 5.5% and 9% for RFA and laser, respectively reported in literature [12–14]. 
To find early signs of a potential future nodule regrowth would be of relevant clinical value. 
Usually, technique efficacy is defined as a volume reduction >50% of the initial volume and is 
evaluated at one year after treatment [15,16]. Recently, some authors introduced initial ablation ratio 
(IAR) as a quantitative early indicator correlated with volume reduction ratio during follow-up [15]. 
In their paper, Sim et al. evaluated the IAR identifying the ablated area on standard B-mode 
ultrasound images [16]. However, some time margins of the ablated area can be difficult to precisely 
delineate on B-mode ultrasound. In this scenario, contrast-enhanced ultrasound (CEUS) is largely 
used after ablation to better identify the ablated area and could improve IAR definition in thyroid 
ablations [17–20]. 
The aim of this study was to compare the reproducibility of CEUS and B-mode and to evaluate 
inter- and intra-observer agreement in the assessment of the radiofrequency-ablated volume of 
benign thyroid nodules, comparing CEUS and B-mode. 
2. Experimental Section 
2.1. Patients 
The local ethics committee approved this study (San Raffaele Hospital Ethics Committee, 
registry number 63/INT/2020). This study was partially supported by Ricerca Corrente funding from 
Italian Ministry of Health to IRCCS Policlinico San Donato. Due to the retrospective nature of this 
study, specific informed consent was waived. 
We retrospectively assessed consecutive patients with predominantly solid nonfunctioning 
thyroid nodules treated with RFA in a single center between January 2014 and December 2016. All 
patients declined or were not eligible for surgery. Benign proven thyroid nodules causing 
compressive symptoms and cosmetic concerns were considered for treatment. 
Eligibility criteria for inclusion in the study were patients who underwent RFA of benign thyroid 
nodules and whose follow-up included CEUS and B-mode evaluation one year after treatment. 
2.2. Preablation Assessment and Procedure 
All patients had a cytologically proven benign, TI-RADS 2 category (benign findings, according 
to the Thyroid Imaging Reporting and Data System) [21] thyroid nodule determining pressure 
symptoms and/or cosmetic problems. 
All procedures were performed under local anesthesia and conscious sedation by one 
interventional radiologist with 10 years of experience in image-guided percutaneous ablations. 
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Under the guidance of a high-resolution linear transducer (L3-12a linear transducer, RS80A with 
Prestige US System—Samsung Medical Imaging, Seoul, South Korea), we used an internally cooled, 
18G electrode with a 0.5–1.5 cm active tip (AMICA, HS Hospital Service, Aprilia, Italy) and a free-
hand “moving-shot” technique [22]. 
2.3. Follow-Up Examinations 
All follow-up US scans were taken one, six, and twelve months after ablation in the same center 
by the same interventional radiologist who performed RFA, using a high-frequency linear probe (L3-12a 
linear transducer, RS80A with Prestige US System—Samsung Medical Imaging, Seoul, South Korea). 
Technical parameters, including gain adjustment, field of view, and transmission focusing, were 
optimized for thyroid imaging. 
Two perpendicular images of the largest ablated area were acquired for each treated nodule with 
CEUS and B-mode 
CEUS evaluation was performed the same day of the B-mode scan, after intravenous 
administration of 4.8 mL of Sonovue (Bracco Imaging, Milan, Italy) with the same US scanner and 
linear probe, using a dedicated preset. 
2.3. Radiofrequency-Ablated Volume Assessment 
Two physicians (V.F. and C.B., with 5 and 6 years of experience in thyroid imaging respectively) 
retrospectively reviewed US images of the last check (one year after treatment) on the Picture 
Archiving and Communication System. They measured the ablated volume on gray-scale B-mode 
images in a first session and on CEUS images in a second session, after two weeks and randomization 
of the cases. To assess intra-observer agreement, a second reading session for both B-mode and CEUS 
scans was performed one month after the first one. 
All measurements were blindly taken in random order and freehandedly. Three orthogonal 
nodule diameters, including the largest diameter, were measured on both B-mode and CEUS images. 
Nodule volume was calculated using the equation V = πabc/6, where V is the volume, a is the longest 
diameter, and b and c are the other two perpendicular diameters. 
2.4. Statistical Analysis 
Inter- and intra-observer agreement was assessed by using the Bland–Altman test. Mean 
difference (bias) and the 95% limits of agreement (mean difference ± 1.96 standard deviation) were 
determined. Statistical analysis was performed using commercial software packages (IBM SPSS 
Statistics for Windows, version 26.0, IBM Corp., Armonk, NY, USA). 
3. Results 
A total of thirty-four patients were treated between January 2014 and December 2016, twenty-
three of whom met the inclusion criteria and were included. Patient and nodule characteristics are 
detailed in Table 1. 
Table 1. Patient and nodule characteristics. 
N 23 
Females/Males 20/3 
Mean age (± standard deviation) 60 (± 14) years 
Nodule location 
Right 9 
Isthmic 3 
Left 11 
Nodule mean volume before treatment (mL) 23.90 ± 17.2 (range 7.3 – 62.5) 
Mean ablated volume (± standard deviation) assessed with CEUS (mL)  
Reader 1 3.947 ± 4.243 
Reader 2 3.729 ± 4.196 
Mean ablated volume (± standard deviation) assessed with B-mode (mL)  
Reader 1 2.441 ± 1.735 
Reader 2 1.562 ± 1.965 
CEUS—contrast-enhanced ultrasound. 
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3.2. Inter-Observer Agreement 
Regarding inter-observer agreement, CEUS showed a bias (95% limits of agreement) of 0.219 mL 
(-0.372 to 0.809 mL) and a coefficient of reproducibility (COR) of 0.593 mL (p = 0861). B-mode had a 
bias of 0.880 mL (-1.655 to 3.414 mL) and a COR of 2.558 mL (p = 0.115). CEUS showed a higher inter-
observer reproducibility (85%) compared to B-mode (27%). 
Reader 1 had higher mean volume estimation compared to Reader 2 using both CEUS and B-
mode. 
Plots are shown in Figure 1. 
 
(A) 
 
(B) 
Figure 1. Bland–Altman plots showing inter-observer reproducibility of measurements for CEUS (A) 
and B-mode (B) assessments. The x-axes show the mean of the volume measurements, and the y-axes 
show the differences between the measurements. Red lines = mean difference between readers, and 
green lines = 95% (1.96 SD) limits of agreement. 
3.3. Intra-Observer Agreement 
Intra-observer agreement was better for CEUS compared to B-mode for both the readers: a bias 
(95% limits of agreement) of 0.013 mL (0.803 to 4.097 mL) was found for Reader 1 assessing his intra-
observer reproducibility assessing ablated volume using CEUS, and 0.031 mL (0.763 to 3.931 mL) for 
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Reader 2. For CEUS, COR was 0.159 mL for Reader 1 (p = 0.992) and 0.190 mL for Reader 2 (p = 0.980), 
and reproducibility was 96% and 95%, respectively. 
The ablated volume assessed with B-mode showed a bias of 0.567 mL (-2.180 to 4.317 mL) and 
0.759 mL (-2.584 to 4.290 mL) for Readers 1 and 2, respectively. For B-mode, COR was 2.203 mL for 
Reader 1 (p = 0.286) and 2.397 mL for Reader 2 (p = 0.169), and reproducibility was 21% and 23%, 
respectively. 
Plots are available as Supplementary Figures 1–4. Figure 2 shows a right nodule ablation results 
evaluation where B-mode US and CEUS are compared. 
 
Figure 2. Case of a 56-year-old woman treated with radiofrequency ablation. (a) Thoracic inlet X-ray 
showing a large retrosternal goiter with left deviation (white arrow) and indentation of the trachea. 
(b) Two-planes gray-scale ultrasound (US) showing pretreatment evaluation of an almost completely 
solid right thyroid lobe nodule (Volume: 28.8 mL). (c) Gray-scale US at 6 months after treatment 
showing volumetric reduction of the ablated nodule (yellow dotted lines = evaluation of the ablated 
area with B-mode US). (d) Contrast-enhanced ultrasound (CEUS) at 6 months after treatment 
demonstrating the area of ablation as an area with lack of enhancement (white crosses = evaluation of 
the ablated area with CEUS). (e) After CEUS-treated nodule evaluation, treatment results can be better 
reconsidered on the grey-scale US (c) showing real ablated nodule margins (yellow dotted lines and 
encircled area) as compared to previously measured margins (white arrows; red encircled area). 
4. Discussion 
Image-guided thermal ablation is becoming increasingly common as an alternative to surgery 
for the treatment of a variety of benign and malignant conditions [23–32]. When dealing with diseases 
in the neck, image-guided thermal ablations have been reported to be effective in the treatment of 
benign thyroid nodules, autonomously functioning nodules, metastatic lymph nodes, and recurrent 
thyroid cancers [9,12,33–37]. In the treatment of benign thyroid nodules, different techniques have 
been used, including laser and RFA, which are the most widely used techniques, and have been 
proven to be effective and with good results over time in terms of nodule volume reduction 
[31,33,34,38–41]. In order to evaluate the success of the procedure, it is crucial to follow treated 
nodules over time. In fact, some of them might regrow and need further ablation sessions. 
US is the most widely used imaging modality for the assessment of thyroid nodules. With B-
mode, a central hypoechoic area is considered as a direct sign of ablation zone (immediately after the 
procedure) and expression of tissue remodeling (during follow-up). From a recent study conducted 
with B-mode, the central ablated area can be used to determine a quantitative index to predict 
therapeutic success [16]. According to this study, IAR is the ratio of the ablated volume to total 
volume of the nodule. If IAR after RFA is <70%, the nodule is likely to regrow [16]. 
However, some limitations of US, such as low reproducibility and operator-depending 
performance and measuring, might reduce its accuracy in the evaluation of thyroid nodules’ ablated 
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volume. Particularly, the ablated area can be difficult to clearly demarcate with B-mode, as it can 
appear as an isoechoic area in comparison with nonablated surrounding thyroid tissue. In this setting, 
CEUS could be helpful in achieving a better demarcation of the ablated area and to improve the 
reproducibility of the measurements. In fact, CEUS provides information regarding the 
vascularization of a human tissue and is widely used in the US assessment of ablations results in 
other organs [18,20,35,36,42]. Furthermore, it is applied in some centers to precisely delineate the 
ablated area in thyroid nodules treated with image-guided thermal ablation [34,37,43]. Notably, US 
contrast agents can be directly administered to complete a standard US examination and are 
extremely safe and well tolerated. In fact, US contrast agents are not excreted through the kidneys 
and can be safely administered to patients with renal insufficiency with no risk of contrast-related 
nephropathy or nephrogenic systemic fibrosis. There is no need for blood tests prior to injection, and 
there is no evidence of any effect on thyroid function, as they do not contain iodine. These contrast 
agents have a very low rate of anaphylactoid reactions (1:7000 patients, 0.014%), significantly lower 
than the rate with iodinated computer tomography (CT) contrast agents (35–95:100,000 patients, 
0.035%–0.095%), comparable to the rate of severe anaphylactoid reactions associated with 
gadolinium-based contrast agents at 0.001%–0.01% [43]. 
In this study, we observed a significantly higher inter- and intra-observer reproducibility in 
measuring the ablated area with CEUS compared to those with B-mode. CEUS, in fact, better 
enhances vascularized tissue, which helps to clarify boundaries between viable and nonviable tissue. 
This could be helpful to obtain a more precise and reproducible measure of the ablated area. In our 
study, it helped in fact to reduce intra- and inter-observer variation. Some studies evaluated the inter-
observer and intra-observer variations assessment of thyroid nodules with US [44–46]. All these 
studies were focused in evaluating the diagnostic performance of US in the diagnosis of malignancy 
among the investigated nodules, while, to the best of our knowledge, no study reported on the 
analysis of inter-observer and intra-observer agreement in the evaluation of the ablated area. Thus, 
our paper is the first to depict the potential role of adding CEUS to standard B-mode ultrasound to 
increase the reproducibility of the measurement of the ablated area after radiofrequency ablation of 
benign thyroid nodules. 
This study has some limitations. First, it is a retrospective study, performed in a single center 
with a low number of cases. Larger prospective studies are necessary to confirm our preliminary 
data. Second, the real value of a precise evaluation of the ablated area is still under investigation, and 
its potential role in predicting a regrowth is still unproven. Therefore, the potential clinical value is 
still hypothetical. Third, the two readers had a quite similar experience in thyroid ultrasound, and 
the variability among operators with larger difference in experience should be further investigated. 
5. Conclusions 
US follow-up is crucial after RFA of benign thyroid nodules. CEUS, compared to conventional 
B-mode, better depicts the ablated area and for this reason reduces variation in its measurement, with 
a significantly higher inter- and intra-observer reproducibility. Thus, application of CEUS during the 
follow-up of patients treated with RFA for a benign thyroid nodule can be beneficial to achieve a 
better definition of the ablated area. Further studies on larger samples are needed to better 
understand the potential clinical value of these findings. 
Supplementary Materials: The following are available online at www.mdpi.com/2077-0383/9/5/1504/s1, Figure 
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